Search results for " Angiotensin receptor blocker"

showing 3 items of 3 documents

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

2012

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups.…

RamiprilMalemedicine.medical_specialtyAmbulatory blood pressureDiastoleAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialRamiprillawInternal medicineInternal MedicinemedicineHumansLongitudinal StudiesTelmisartanAntihypertensive AgentsAgedbusiness.industryambulatory blood pressure antihypertensive treatment high cardiovascular risk angiotensin-converting enzyme inhibitors angiotensin receptor blockersMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedEndocrinologyBlood pressureTreatment OutcomeTarget drugAmbulatoryHypertensionCardiologyBenzimidazolesDrug Therapy CombinationFemaleTelmisartanbusinessmedicine.drug
researchProduct

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis…

2020

Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, compar…

0301 basic medicineMalePhysiologyMiddle Aged Renin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE-I; ARB; COVID-19; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mortality; sartansSeverity of Illness IndexRenin-Angiotensin System0302 clinical medicineangiotensin converting enzyme inhibitorsRisk FactorsACE-I80 and overMedicineHospital MortalitySartanAged 80 and overIncidence (epidemiology)IncidenceHazard ratioAngiotensin Receptor AntagonistMiddle AgedsartansARBHospitalizationAntihypertensive AgentItalyMeta-analysisHypertensionSartansMolecular MedicineFemaleRisk assessmentHumanmedicine.medical_specialtyAngiotensin converting enzyme inhibitors; ACE-I; Angiotensin receptor blockers; ARB; Sartans; COVID-19; MortalityCoronavirus disease 2019 (COVID-19)Risk AssessmentArticleCOVID−1903 medical and health sciencesAngiotensin Receptor AntagonistsMeta-Analysis as TopicInternal medicineSeverity of illnessHumansAngiotensin receptor blockerMortalityAntihypertensive AgentsAgedPharmacologyACE-I; ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; COVID−19; Mortality; Sartans; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Female; Hospitalization; Humans; Hypertension; Incidence; Italy; Male; Meta-Analysis as Topic; Middle Aged; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Hospital Mortalitybusiness.industryRisk FactorCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin receptor blockersmortalityConfidence intervalangiotensin receptor blockersAngiotensin converting enzyme inhibitors030104 developmental biologyACE-I; ARB; COVID-19 angiotensin converting enzyme inhibitors angiotensin receptor blockers mortality sartansObservational studyAngiotensin converting enzyme inhibitorbusiness
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct